Nature’s Bioceuticals Enters into Contractual Agreement to Purchase Breakthrough Sinusitis Formula
CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire/ — Nature’s Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it has come to an agreement for the purchase of the newly formulated Sinus-Restore Sinus Relief Formula. Nature’s has tendered a deposit against formal closing, which is expected within 3 weeks. At the request of the inventor, to protect his privacy, financial terms are not to be disclosed in press releases.
The Center for Disease Control and Prevention estimates that close to 31 million adults in the US suffer from chronic sinusitis, resulting in 12.5 million ambulatory care visits per year and more than 200,000 sinus surgical procedures every year. Acute sinusitis is even more common, though there are no good estimates for the number of people who experience an episode of acute sinusitis every year.
Robert deZanger, CEO of Nature’s Bioceuticals states, “We are excited about bringing this product to market. Approximately 13% of the adult population suffers from chronic sinusitis. Billions of dollars per year are wasted on doctor visits and antibiotics that are unnecessarily prescribed to treat viral infections for which they will not help. Our all natural product has been shown to provide relief in a few short days. We expect to finalize the purchase within the next 21 days and to have product manufactured and ready for sale approximately 21 days thereafter. The product should also have far reaching impact for the relief of nasal discomfort due to allergies and cold and flu. The product is inexpensive to produce and we believe it will command a substantial market share in the three different markets therefore producing substantial revenues for the company. We anticipate sales in excess of $10,000,000.00 the first year and then expanding exponentially thereafter.”
About Nature’s Bioceuticals:
Nature’s Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature’s Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today’s prescribed drugs.
Nature’s line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as “DSHEA”
In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature’s Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature’s Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as “expects,” “intends,” “believes,” “anticipates,” “should,” “likely,” and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature’s Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company’s financial statements by the Company and its Audit Committee; modification of the Company’s accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
Phone Number: 888 656 3509
SOURCE Mistral Ventures Inc.